10/20/2022 8:14:35 AM
Revance Submits Supplemental BLA For DAXXIFY For Injection For Cervical Dystonia
9/8/2022 7:05:02 AM
Revance : FDA Approves DAXXIFY For Injection For Temporary Improvement Of Moderate To Severe Frown Lines
3/21/2022 8:09:22 AM
Revance Closes On $300 Mln Note Purchase Agreement With Athyrium Capital Management
1/7/2022 8:06:33 AM
Revance Expects Preliminary Q4 RHA Collection Revenue To
be $23.0 Mln And $24.0 Mln
10/11/2021 8:12:15 AM
Revance Launches OPUL, The First-of-its-Kind Relational Commerce Platform For Aesthetic Practices
9/16/2021 8:13:42 AM
Revance To Showcase Data From Phase 3 Trial Evaluating Efficacy, Duration Of Effect And Safety Of DaxibotulinumtoxinA
9/10/2021 8:12:43 AM
Revance Presents Data On RHA Collection Of Dermal Fillers At 2021
Virtual Skin Of Color Update Meeting
5/26/2021 8:28:16 AM
Revance: FDA To Initiate Pre-approval Inspection Of Manufacturing Facility For DaxibotulinumtoxinA By End Of June
4/27/2021 8:17:55 AM
Revance Says First Patient Enrolled For DaxibotulinumtoxinA In Glabellar Lines And Cervical Dystonia By Fosun Pharma
1/7/2021 8:24:40 AM
Revance Maintains Strong Balance Sheet; Reaffirms Its Expectations To Be Funded Into 2023
3/1/2018 9:04:13 AM
William Blair Reiterates Revance Therapeutics, Inc. (RVNC) At Outperform